Professor Adam McCluskey has in the chemical biology of endocytosis, in particular the development of novel therapies centred on the modulation (inhibition and stimulations) of two key proteins: clathrin and dynamin. Targeting these proteins, his team is exploring new drug targets in cancer, epilepsy, neuropathic pain and kidney disease using cutting edge flow chemistry approaches.
Optimising choice, dose and timing of medicines for a particular patient are the focus of the clinical work and research career of Professor Jennifer Martin, inaugural Co-Director of the PRC. Jennifer co-leads the Centre for Human Drug Research which focuses on taking molecules from the clinic into early phase human trials, and trials of rational combination therapies to enhance clinical outcomes.
Professor Neilan is an expert in molecular microbiology, genetic and genomic engineering and microbial chemistry. His team uses synthetic biology tools to discover and manufacture bioactive small molecules, including antibiotics, biotoxins, food preservatives and UV-absorbers.
Pharmacy and Experimental Pharmacology
Conjoint Professor Stephen Ackland’s research expertise are in the areas of basic and clinical pharmacology of anticancer drugs, including drug measurement, pharmacokinetics pharmacodynamics, and relevant genetics/genomics. Clinical trials in cancer mainly medical oncology.